Minocycline in Huntington's disease: A pilot study

Abstract

Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6‐month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini‐Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted. © 2004 Movement Disorder Society